Drug intelligence / Profile preview

AlloRx

Development stage: Phase 1
Lead developer: Vitro Biopharma
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intravenous, Topical

Overview

AlloRx is an allogeneic, umbilical cord-derived mesenchymal stem cell (MSC) therapy developed by AlloSource. It is designed to leverage the innate immunomodulatory and regenerative properties of MSCs to treat inflammatory and tissue-damaging conditions. The therapeutic mechanism involves the secretion of paracrine factors—including cytokines, chemokines, and extracellular vesicles—that modulate the activity of immune cells such as T-cells and macrophages, thereby reducing systemic inflammation and promoting tissue healing. AlloRx has been investigated in clinical settings for indications including COVID-19-related acute respiratory distress syndrome (ARDS) and chronic wounds like diabetic foot ulcers.

Brand names: AlloRx
Other names: Umbilical Cord-Derived Mesenchymal Stem CellsUC-MSCs

Beyond the preview

Go deeper on AlloRx.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AlloRx.

Explore the full profile